Company Name, Ticker, Customers, else..

Repligen Corp (RGEN)

Other Ticker:

Sector • Healthcare Industry • Biotechnology & Pharmaceuticals

Industry • Biotechnology & Pharmaceuticals

Sector • Healthcare

Repligen Corp

RGEN's Fundamental analysis

Select the Comparisons :

None ▼

Select the Ratio:

None▼

None ▼

None▼

RGEN Growth rates comparisons

Looking into Repligen growth rates, revenue grew by 0.13 % in IV. Quarter 2022 from the same quarter a year ago. Ranking at No. 1079

Biotechnology & Pharmaceuticals industry recorded deterioration of revenues by -4.71 %

Repligen's net income grew by 67.4 % in IV. Quarter 2022 year on year, above company average,

• More on RGEN's Growth

RGEN's Valuation comparisons

Repligen
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Repligen PEG ratio is at 1.18 Repligen realized cash outflow of $ 0per share in trailing twelve-month period.

Company

53.39

PE TTM

Industry

-

PE TTM

Company's Price to Sales ratio is at 12.46.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.57.

• More on RGEN's Valuation

Total Debt (Millions $)	285
Dividend TTM ($)	0 $
Dividend Yield TTM (%)	-
Revenue/Employee (TTM) $	-
Net Income/Employee (TTM) $	-
Receivable Turnover (TTM)	6.72
Tangible Book Value (Per Share $)	12.22

RGEN's Valuation comparisons

Repligen
current PE on trailing twelve month basis is above Biotechnology & Pharmaceuticals industry average.

Repligen PEG ratio is at 1.18 Repligen realized cash outflow of $ 0per share in trailing twelve-month period.

Company

53.39

PE TTM

Industry

-

PE TTM

Company's Price to Sales ratio is at 12.46.
Biotechnology & Pharmaceuticals industry's Price to Sales ratio is at 5.57.

Repligen Price to Book Ratio is at 5.23 higher than Indusry Avg. of -0.02, and higher than S&P 500 Avg. of -0.01

• More on RGEN's Valuation

• Market Capitalization (Millions $)	9,990
• Shares Outstanding (Millions)	57
• Employees	-
• Revenues (TTM) (Millions $)	802
• Net Income (TTM) (Millions $)	186
• Cash Flow (TTM) (Millions $)	-
• Capital Exp. (TTM) (Millions $)	-
• Total Debt (Millions $)	285
• Dividend TTM ($)	0 $
• Dividend Yield TTM (%)	-
• Revenue/Employee (TTM) $	-
• Net Income/Employee(TTM) $	-
• Receivable Turnover Ratio (TTM)	6.72
• Tangible Book Value (Per Share $)	12.22

• Market Capitalization (Millions $)	9,990
• Shares Outstanding (Millions)	57
• Employees	-
• Revenues (TTM) (Millions $)	802
• Net Income (TTM) (Millions $)	186
• Cash Flow (TTM) (Millions $)	-
• Capital Exp. (TTM) (Millions $)	-

RGEN's Profitability Comparisons
Repligen faced margin deterioraten, primarily through cost pressure. Operating Margin fell in IV. Quarter 2022 to 26.15 % from 26.24 % in III. Quarter. Repligen net profit margin of 26.09 % is currently ranking no. 14 in Biotechnology & Pharmaceuticals industry, ranking no. 42 in Healthcare sector and number 571 in S&P 500.

	*Ratio*
• Capital Ratio (MRQ)	2.51
• Total Debt to Equity (MRQ)	0.15
• Tangible Leverage Ratio (MRQ)	0.87
• Asset Turnover Ratio (TTM)	0.33
• Inventory Turnover Ratio (TTM)	1.48

RGEN's Profitability Comparisons

Repligen faced margin deterioraten, primarily through cost pressure. Operating Margin fell in IV. Quarter 2022 to 26.15 % from 26.24 % in III. Quarter.

Repligen net profit margin of 26.09 % is currently ranking no. 14 in Biotechnology & Pharmaceuticals industry, ranking no. 42 in Healthcare sector and number 571 in S&P 500.

• More on RGEN's Key Ratios


Economy Advance Monthly Sales Consumer Price Index CPI Producer Price Index PPI Retail Inventories Personal Income Gross Domestic Product GDP Money Supply Industrial Production Productivity Employment Situation US International Trade Factory Orders Durable Goods Construction Spending Housing Starts Vehicle Unit Sales	Stocks Event Calendar DSGN's Profile Stock Price DSGN's Financials Business Description Fundamentals Charts & Quotes DSGN's News Suppliers DSGN's Competitors Customers & Markets Economic Indicators DSGN's Growth Company Segments	Screening Stock Performance Growth Rates Profitability Valuation Dividend Financial Strength Efficiency Largest Companies Management Effectivness

Help

Sitemap

Advertise

About us

Glossary

Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071